Hormone-based therapies like GLP-1 receptor agonists show promise for treating fatty liver disease and potentially preventing its progression to liver cancer.
#1 chronic liver diseaseMASLD is now the most common chronic liver condition in Western countries
What the researchers found
GLP-1 receptor agonists and related hormone therapies can resolve MASH without worsening fibrosis, potentially preventing progression to liver cancer.
Why it matters
Liver cancer from fatty liver disease is rising rapidly, and effective prevention strategies are urgently needed beyond lifestyle changes alone.
The numbers in context
Reviews GLP-1 RA effects on MASH resolution, fibrosis, and HCC risk. Observational data suggest reduced liver-related morbidity. Benefits less evident in cirrhosis.
How the study worked
Narrative review of clinical and preclinical evidence on nutrient-stimulated hormone therapies for MASLD/MASH and HCC prevention.
Who was studied
Patients with MASLD/MASH at risk for HCC
What this study cannot tell us
As a review, it synthesizes existing evidence without generating new data. Long-term cancer prevention outcomes with these therapies remain unproven.
How to read the evidence
Review article synthesizing clinical and preclinical data — provides a strong rationale but lacks direct cancer prevention trial results.
When this study was published
Published in 2025, reflecting the latest understanding of GLP-1 therapies in liver disease.
The bigger picture
This positions GLP-1 drugs as potential cancer-prevention tools, extending their therapeutic reach far beyond diabetes and obesity management.
Questions still open
- How long must patients take GLP-1 drugs to meaningfully reduce liver cancer risk?
- Do these benefits persist in patients who already have cirrhosis?
Common questions
Can GLP-1 drugs prevent liver cancer?
What is MASH and why does it matter?
Read the original research
Nutrient-stimulated Hormone-based Therapies: A New Frontier in the Prevention and Management of MASH-associated Hepatocellular Carcinoma.
Journal of clinical and translational hepatology, 13(12), 1060-1066
Citation
Phillips, Richard; Ma, Yuk Ting; Hanif, Wasim; Shah, Tahir; Sivakumar, Shivan. (2025). Nutrient-stimulated Hormone-based Therapies: A New Frontier in the Prevention and Management of MASH-associated Hepatocellular Carcinoma.. Journal of clinical and translational hepatology, 13(12), 1060-1066. https://doi.org/10.14218/JCTH.2025.00303